Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter study of rituximab plus local radiotherapy for newly diagnosed early MALT lymphoma
ChiCTR2000036318Phase 4Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: 2-year progression-free survival rate. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on ChiCTR2000036318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036318.